Scienture Holdings, Inc. (SCNX)
| Market Cap | 5.73M -85.0% |
| Revenue (ttm) | 821,315 +540.6% |
| Net Income | -37.95M |
| EPS | -32.46 |
| Shares Out | 1.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,040 |
| Open | 3.310 |
| Previous Close | 3.400 |
| Day's Range | 3.310 - 3.680 |
| 52-Week Range | 2.640 - 27.750 |
| Beta | 4.08 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About SCNX
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It al... [Read more]
Financial Performance
Financial StatementsNews
Scienture price target lowered to split-adjusted $6 at Maxim
Maxim lowered the firm’s price target on Scienture (SCNX) to $6 from $37.50 and keeps a Buy rating on the shares. The firm cites the company’s below-consensus Q3 revenue pre-announcement…
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli ™ Growth and the Commercial Launch of REZENOPY ™
Scienture reports preliminary Q3 revenue $1.22M, consensus $1.58M
“These preliminary third-quarter revenue results mark a significant inflection point for Scienture (SCNX), demonstrating the accelerating commercial momentum of our expanding pharmaceutical portfolio,...
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth
Scienture Holdings Inc trading halted, news pending
19:50 EDT Scienture (SCNX) Holdings Inc trading halted, news pending
Scienture’s Arbli added to formularies at 3 U.S. pediatric academic med centers
Scienture (SCNX) announced that Arbli Oral Suspension, 10 mg/mL has been added to the formulary of three U.S. pediatric academic medical centers and hospitals specializing in the treatment of children...
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Major Institutional Formulary Win Expands Arbli ™ 's Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
Scienture announces reverse stock split
Scienture (SCNX) announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split is…
Scienture Holdings, Inc. Announces Reverse Stock Split
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providin...
Scienture expands commercial reach of Rexenopy to Addiction Treatment Centers
Scienture (SCNX) announced that its wholly owned subsidiary, Scienture, has entered into an exclusive Sales, Marketing and Distribution Agreement with a distribution partner to provide opioid and subs...
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™
Scienture announces commercial launch of Rezenopy Nasal Spray
Scienture (SCNX) announced the commercial launch of Rezenopy Nasal Spray 10 mg, including the fulfillment of its first purchase orders to U.S. pharmaceutical wholesalers.
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2...
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™
Scienture to begin shipments of Rezonopy to wholesalers
Scienture (SCNX) announced that it has completed manufacturing of commercial launch inventory and will begin shipments later this month of Rezonopy Nasal Spray 10 mg to U.S. pharmaceutical wholesalers...
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray
Scienture announces progress in commercialization of Arbli
Scienture (SCNX) announced significant progress in the commercialization of Arbli, including expanded payor coverage, broader pharmacy access, new channel partnerships, and ongoing initiatives designe...
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value...
Scienture reveives U.S. patent covering Rezenopy Nasal Spray
Scienture (SCNX) announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,622,903 B2, patent covering Rezenopy Nasal Spray 10 mg, effective May 12, with an…
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existin...
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing ...
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment